Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.

NCT01218633 is registered in ClinicalTrials.gov with Adrian Vella as lead sponsor.

NCT NCT01218633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01218633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.
Lead sponsor
Adrian Vella
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2012
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic effects of 9,39-exendin and 9,36-glp-1